 CAMBRIDGE, Mass., Nov. 19, 2020 GLOBE NEWSWIRE -- Cue Biopharma, Inc. Nasdaq: CUE, a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patients body, announced today that the company has extended the term of the research program under its existing 2017 research collaboration and license agreement with Merck toward developing a clinical candidate for the treatment of type 1 diabetes and an additional undisclosed autoimmune disease. 